Clinical Trials Browser

Phase 3 × Urinary Bladder Neoplasms × Genitourinary × Clear all

NCT07218380 2026-04-17

FORAGER-2

Phase 3 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04960709 2026-04-14

VOLGA

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03775265 2026-04-13

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04579224 2026-04-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04658862 2026-04-13

SunRISe-2

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT05092958 2026-04-13

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05714202 2026-04-13

SunRISe-3

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT07419295 2026-04-13

TroFuse-031

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT05911295 2026-04-07

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07000084 2026-04-07

GAIN-BCG

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT05037279 2026-03-20

EVER

Phase 3 Recruiting

Urinary Bladder Neoplasms, Recurrence

NCT07480356 2026-03-18

ADVANCED-3

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT07313891 2026-03-17

BOOST

Phase 3 Withdrawn

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT07464145 2026-03-11

RESCUE

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03682068 2026-02-03

NILE

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT06703476 2026-01-27

A Study of Surgical Techniques During Cystectomy

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT04165317 2026-01-22

CREST

Phase 3 Active not recruiting

1,068 enrolled 20 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06331299 2026-01-15

UTOPIA

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Phase 3 Completed

608 enrolled 22 charts 2 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06747455 2025-12-23

BCG for Therapeutic Use Phase Ⅲ Clinical Trial

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05726786 2025-12-09

INCyst

Phase 3 Recruiting

Cystitis, Hemorrhagic, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urinary Bladder, Neurogenic, Endometriosis, Cystitis, Interstitial, Malnutrition

NCT06525571 2025-11-18

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT01812369 2025-10-06

VESPER

Phase 3 Completed

Urinary Bladder Neoplasms

NCT04149574 2025-09-16

CheckMate 7G8

Phase 3 Terminated

13 enrolled 11 charts

Urinary Bladder Neoplasms

NCT04534075 2025-09-08

FIDURA

Phase 3 Completed

GastrointestinalGenitourinaryGynecologic

Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Flatulence, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

NCT03924856 2025-08-28

KEYNOTE-866

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03924895 2025-08-28

KEYNOTE-905

Phase 3 Active not recruiting

595 enrolled 3 FDA

Urinary Bladder Neoplasms

NCT05704244 2025-08-28

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT07067749 2025-07-24

TEMPO-MIBC

Phase 3 Recruiting

Urinary Bladder Neoplasms, Neoplasms

NCT04574960 2025-07-20

NAUTICAL

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT03757949 2025-05-15

Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

Phase 3 Active not recruiting

203 enrolled 9 charts

Urinary Bladder Neoplasms

NCT05776758 2025-04-16

Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT02807636 2025-02-24

IMvigor130

Phase 3 Completed

1,213 enrolled 35 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06364904 2025-02-21

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT02951325 2025-02-13

BART

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03799835 2024-12-11

ALBAN

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04806178 2024-12-09

IMMUNOBCG

Phase 3 Completed

Urinary Bladder Neoplasms

NCT04241185 2024-11-25

MK-3475-992

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT01627197 2024-11-05

Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer

Phase 3 Completed

Urinary Bladder Neoplasms

NCT05243550 2024-11-04

ENVISION

Phase 3 Active not recruiting

240 enrolled 20 charts 3 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05600322 2024-10-03

Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer

Phase 3 Completed

158 enrolled 9 charts

Urinary Bladder Neoplasms

NCT05136898 2024-09-19

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Completed

8 enrolled 18 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05822934 2024-07-30

Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms